The FDA Pharmacy Compounding Advisory Committee Meeting, July 2026: What Is on the Agenda

Educational content only. Not medical advice. FeelGood does not claim that any peptide treats, cures, prevents, or mitigates any disease or condition. Consult a qualified healthcare provider before making any decisions about peptide therapy.

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee will convene in Silver Spring, Maryland, to review seven peptides for possible inclusion on the 503A Bulks List of bulk drug substances that licensed compounding pharmacies may use to prepare custom medications. The decisions the committee reaches and the rulemaking that follows them will reshape the legal peptide market in the United States.

The meeting agenda is unusually consequential. The peptides under review include several that account for the largest share of current research-chemical channel sales (BPC-157, KPV, TB-500) and several that anchor the longevity and cognitive research literature (epitalon, semax, DSIP). The FDA's regulatory posture toward each of these compounds will move from "Substances with Safety Concerns" toward either "may be compounded" or "may not be compounded" pending the committee's recommendations and the agency's response.

This article describes what PCAC is, how the 503A Bulks List process works, what is specifically on the July agenda, and what the possible outcomes look like for the broader peptide market.

What the Pharmacy Compounding Advisory Committee does

The Pharmacy Compounding Advisory Committee is a standing advisory committee to the FDA, established under the Drug Quality and Security Act of 2013. PCAC reviews questions related to compounded drug products and advises the agency on which bulk drug substances should be included on the 503A Bulks List, the formal list of substances licensed compounding pharmacies are permitted to use under Section 503A of the Federal Food, Drug, and Cosmetic Act.1

The committee's role is advisory. Its recommendations do not have force of law. The FDA considers PCAC recommendations in its rulemaking process, which is the formal mechanism that adds substances to or removes them from the 503A Bulks List. Under the Administrative Procedure Act, FDA rulemaking moves through a notice-and-comment cycle that typically takes six to twelve months after a PCAC recommendation, sometimes longer.2

The committee's deliberations are public. The FDA's docket for each meeting is published in the Federal Register and includes the briefing documents the committee will review, the public comments submitted, and the meeting agenda. The Federal Register docket for the July 2026 meeting is FDA-2025-N-6895. The public comment period for the docket closes on July 22, 2026.3

The 503A Bulks List and where peptides sit on it

Under Section 503A of the FDCA, licensed compounding pharmacies may prepare custom medications using bulk drug substances that meet one of three criteria: the substance is the subject of an FDA-approved drug, the substance is the subject of an applicable USP or NF monograph, or the substance appears on the 503A Bulks List.4

The 503A Bulks List is divided operationally into three categories during the interim period that has now persisted for several years. Category 1 contains substances under consideration for the final list, which 503A pharmacies are permitted to use during the evaluation period. Category 2 contains substances flagged for safety concerns, which 503A pharmacies are not permitted to use. Category 3 contains substances under evaluation that do not raise the same safety questions as Category 2 but are not yet cleared.5

In 2023, the FDA placed 19 peptides on Category 2, including BPC-157, KPV, TB-500 (thymosin beta-4 fragment), CJC-1295, ipamorelin, MOTs-C, and several others. The placement on Category 2 effectively prohibited 503A compounding pharmacies from preparing those compounds, which is one of the principal reasons the consumer demand for those compounds migrated into the research-chemical channel. The Category 2 placement was not a final regulatory determination. It was a precautionary step pending further review. That review is what the July 2026 PCAC meeting is conducting.6

What is on the July agenda

The FDA's published meeting notice lists the substances under review across the two days.

Day one, July 23, 2026. The agenda focuses on the higher-volume Category 2 peptides: BPC-157, KPV, TB-500, and MOTs-C. These are the compounds with the largest current grey-market presence and the most extensive consumer-marketing infrastructure. The committee will consider the available safety data, characterization data, manufacturing data, and any clinical evidence submitted.

Day two, July 24, 2026. The agenda turns to a different set of compounds with stronger roots in the longevity and cognitive research literatures: DSIP (delta sleep-inducing peptide), Semax (the heptapeptide ACTH analog developed in Russian research), and Epitalon (the Khavinson-program tetrapeptide). These compounds have smaller commercial footprints than the day-one set but longer continuous research histories, primarily from Russian and Eastern European laboratories.7

The day-two compounds occupy an unusual regulatory position. They are not the focus of the FDA's enforcement attention in the way BPC-157 has become. They also have not been broadly evaluated in Western clinical trials, which means the committee will be working from a literature base that is real, longstanding, and almost entirely outside the regulatory submissions that typically inform PCAC reviews. How the committee responds to that situation will be informative about the FDA's posture toward longevity-relevant compounds more broadly.

How PCAC reviews bulk drug substances

The committee evaluates each substance against a defined set of considerations. The principal questions are whether the substance can be characterized with sufficient identity and purity for compounding use, whether the substance raises safety concerns when used in compounded preparations, whether there is historical use of the substance in compounded preparations, and whether there is clinical need that compounded preparations would address.8

For the seven peptides on the July agenda, each of these considerations will produce different answers.

BPC-157 has the largest current research-chemical market presence, the most extensive consumer marketing, and the most recent FDA enforcement attention. The safety database, in the strict sense the FDA evaluates, is modest: there are limited human trials, mostly small and short-duration. The historical-use case for 503A compounding is moderate; the clinical-need case is debated.9

KPV (Lys-Pro-Val) has a smaller commercial footprint and a research base concentrated in inflammatory and dermatologic preclinical studies. Its safety profile in the published literature is favorable but the human trial base is also limited.

TB-500 is the synthetic fragment of thymosin beta-4. Its characterization is straightforward; its clinical evidence base in humans is preliminary.

MOTs-C is a mitochondrial-derived peptide with a research base in metabolic and longevity preclinical models. Its safety and characterization data are less mature than the older compounds.

The day-two compounds (DSIP, Semax, Epitalon) carry the unusual feature noted above: substantial publication histories, almost entirely from non-US research laboratories, with much of the work in journals that do not appear in the FDA's typical submission pathways.

Possible outcomes and what they would mean

The committee's recommendations will likely sort the seven compounds across at least three outcome categories.

Recommendation for inclusion on the Bulks List. A compound with adequate characterization, acceptable safety profile, and credible clinical use case is recommended for inclusion. After the FDA's rulemaking process, the compound becomes legal for 503A pharmacy compounding. This is the outcome most favorable to the broader peptide market. It also moves the compound out of the research-chemical channel and into the regulated pharmacy channel, which has implications for how brands like FeelGood (and the integrative medicine community generally) will distribute the compound going forward.

Recommendation against inclusion. A compound with inadequate characterization or unresolved safety concerns is recommended against inclusion. The compound remains in Category 2 and cannot be legally compounded. This is the outcome most unfavorable for the commercial channels currently distributing the compound. It also tends to be the outcome that triggers stepped-up FDA enforcement against grey-market distribution.

Mixed outcome, recommendation for further review. The committee may recommend that additional data be developed and that the substance be reconsidered at a future meeting. This is the outcome that perpetuates the current limbo state.

The base case for the July meeting, based on the published briefing materials and the substances' respective evidence bases, is a mixed outcome across the seven compounds. BPC-157 is the most likely candidate for a favorable recommendation given the depth of the research base and the broad commercial interest, though the committee may attach data-development conditions. KPV and MOTs-C are likely to be reviewed more cautiously given the less mature human data. The day-two compounds (DSIP, Semax, Epitalon) are difficult to predict because PCAC has not previously reviewed a class of compounds with this particular evidence profile.10

The rulemaking timeline that follows

PCAC recommendations do not change the legal status of any substance directly. The FDA must initiate rulemaking under the Administrative Procedure Act to formally add a substance to the 503A Bulks List, including a proposed rule, public comment period, and final rule. The timeline from PCAC recommendation to final rule typically runs six to twelve months at minimum, sometimes longer if the rule attracts substantial comment or if the FDA elects to consolidate multiple substances into a single rulemaking.11

This means that even a favorable PCAC recommendation in July 2026 does not produce a compounding pathway in the same calendar year. Compounding pharmacies that anticipate post-recommendation supply will need to plan for the rulemaking lag. Brands that anticipate transitioning compounds from the research-chemical channel into a regulated pharmacy channel will need to time their commercial moves to the rulemaking, not to the PCAC vote itself.

What the meeting signals about the broader regulatory environment

The July 2026 PCAC meeting is the first time the agency has reviewed peptides at this scale since the 2023 Category 2 placements. The agency's posture toward the substances reviewed will indicate how the FDA is thinking about the peptide segment going forward.

A favorable posture across multiple compounds would signal that the FDA sees the regulated 503A pathway as the right home for the broader peptide category, with enforcement focused on grey-market distribution channels that fall outside that pathway. An unfavorable posture would signal that the agency views most of the current peptide market as outside the appropriate scope of compounded preparations, with implications both for the research-chemical channel and for the future development of FDA-approved peptide drugs.

The reporting in the legal and trade press through the run-up to the meeting suggests cautious optimism about a favorable outcome for at least some of the compounds, though with substantial uncertainty across the slate.12 The MIT Technology Review piece from February 2026 framed the meeting as a near-inflection point for the legal peptide market.13 BioPharma Dive's April 2026 coverage of the agency's April 15 announcement of the meeting indicated the FDA was approaching the slate with an eye toward "easing restrictions on certain peptides," language that hints at a more permissive direction than the 2023 Category 2 placements.

The meeting will resolve some of that uncertainty. Editorial coverage and commentary on the outcomes will follow.

Footnotes

1. FDA, "Pharmacy Compounding Advisory Committee." https://www.fda.gov/advisory-committees/human-drug-advisory-committees/pharmacy-compounding-advisory-committee
   
2. National Law Review, "Tiny Chains, Big Changes," explaining the formal rulemaking timeline following PCAC recommendations. [verify exact URL and date]
3. Federal Register Docket FDA-2025-N-6895. https://www.regulations.gov/docket/FDA-2025-N-6895. Public comment period open through July 22, 2026; comments submitted by July 9 are circulated directly to PCAC committee members.
4. Federal Food, Drug, and Cosmetic Act, Section 503A. https://www.fda.gov/drugs/human-drug-compounding/section-503a-federal-food-drug-and-cosmetic-act
   
5. Frier Levitt, "Regulatory Status of Peptide Compounding in 2025," January 2026. https://www.frierlevitt.com/articles/regulatory-status-of-peptide-compounding-in-2025/
   
6. FDA, 503A Bulks List interim categories. The Category 2 designation for the 19 peptides in question was published in the Federal Register in 2023. [verify specific Federal Register citation]
7. FDA, "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee," published April 15, 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
   
8. FDA, "Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act." Guidance for Industry. [verify guidance document URL]
9. STAT News, "BPC-157: The peptide with big claims and scant evidence," February 2026. https://www.statnews.com/2026/02/03/bpc-157-peptide-science-safety-regulatory-questions/
   
10. Frier Levitt, "FDA to Remove 12 Popular Peptides from the Category 2 'Do Not Compound' List," April 2026. https://www.frierlevitt.com/articles/fda-peptides-do-not-compound-list-update-2026/
    
11. Administrative Procedure Act, 5 U.S.C. § 553, governing federal rulemaking process and notice-and-comment requirements.
12. RAPS, "FDA considers adding a dozen peptides to its bulk drug compounding list," April 2026. https://www.raps.org/resource/fda-considers-adding-a-dozen-peptides-to-its-bulk-drug-compounding-list.html
    
13. MIT Technology Review, "Peptides are everywhere. Here is what you need to know," February 2026. https://www.technologyreview.com/2026/02/23/1133522/peptides-are-everywhere-heres-what-you-need-to-know/